Copenhagen, Denmark - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company owned by Novo Holdings A/S, today reported its financial results for the year ending December 31, 2017 and provided an update on its product portfolio. Xellia is focused on providing important anti-infective treatments against serious and often life-threatening infections.
Irvine, CA, Amsterdam, Netherlands – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing (NGS)-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe.
Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, today announces that Dani Bach has been appointed as Non-Executive Director of the Company with immediate effect. Dani replaces Rob Woodman as the representative for IP Group plc., now one of the largest shareholders of the Company.
Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in Life science microbiome investment, today announces that it has launched AVF, the innovative venture capital fund, targeted at supporting companies in the field of animal health, feed and nutrition. The first close of AVF at €24m, is corner stoned by Adisseo, an industry leader in the animal feed sector.
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has been appointed by Jazz Pharmaceuticals plc (NASDAQ: JAZZ, ‘Jazz’) to distribute Vyxeos® (daunorubicin and cytarabine) liposome for injection via a Managed Access Program (‘MAP') outside the United States.
London & Geneva & Jersey – Medicxi, the leading European life sciences investment firm, today announces a new initiative named ‘The Foundation Institute for 21st Century Medicine’ based in Cambridge, U.K. (‘The Foundation Institute’ or ‘C21Med’).
Naarden, The Netherlands – Forbion, one of the leading European life science venture capital firms, today announces that H. Lundbeck A/S (Lundbeck) has acquired Forbion’s portfolio company Prexton Therapeutics B.V. (Prexton) for a total consideration of EUR 905 million (USD 1.1 billion).
Cambridge, UK – Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.
Naarden, The Netherlands – 13 March 2018 – Forbion, one of the leading European life science venture capital firms, today announced that it led the $19 million Series B financing of Escalier Biosciences BV, a privately held biopharmaceutical company based in Nijmegen, The Netherlands. Escalier Biosciences is developing both oral and topical RORγt drug candidates for psoriasis and other autoimmune diseases.
Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the discovery, design, development and manufacture of biopharmaceutical products, has signed an agreement to access a major cell line depository.
Sydney, Australia – Recce Pharmaceuticals Ltd (ASX: RCE), the company developing a new class of synthetic antibiotics, today announced it has been invited to attend a face-to-face meeting with the US Food and Drug Administration (FDA) to discuss its unique technology and proposed clinical and regulatory pathway for its lead synthetic antibiotic compound RECCE® 327.
Groningen, The Netherlands – Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices, today announced that the US Food and Drug Administration (FDA) has granted Polyganics’ request for Breakthrough Device designation to its Liver and Pancreas Sealant Patch. The Liver and Pancreas Sealant patch is considered a unique breakthrough in the prevention of fluid leakage after hepato-pancreato-biliary (HPB) procedures, for which currently no approved or cleared alternatives exist.
Cambridge, UK – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Bobby Soni to its Board of Directors with immediate effect. Bobby replaces Rob Woodman as the representative for IP Group plc.
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed Terry Walsh as Senior Vice President of Clinical Trials Services (‘CTS’). Clinigen has also promoted Benjamin Miny, the former Managing Director of Clinigen South Africa, to Senior Vice President of Commercial Medicines.
Cambridge, UK – Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.
LONDON, BOSTON, SAN FRANCISCO, TOKYO – Drug makers entered 2017 fearing the worst about retaining their US pricing power. They exited the year more jubilant, since on most measures, 2017 delivered a resurgence for pharma and biotech. The picture was similar for the medical technology industry, though life got tougher for smaller groups. In biopharma, drug approvals in the US jumped, the IPO window was thrown open and venture funding soared. However, concerns about the growth prospects of large drug developers led to a disappointing year for some big pharma groups. In the device sector M&A activity increased markedly and all the big players saw their share prices head skywards. However, it was a dismal story on the funding and IPO front, continuing a trend that has lasted for several years.
Cambridge, UK – Congenica, a global provider of clinical genomics interpretation software, announced today that it has received certification in ISO 13485:2016, a quality management system for medical devices that supports comprehensive policies and processes across the entire business.
MELBOURNE, Australia – Dimerix Limited or the “Company” (ASX: DXB), a clinical-stage biotechnology company developing new therapeutic treatments using its proprietary assay technology has raised an additional AU $4.5 million through the issue of 37,500,000 shares at 12 cents per share to wholesale and institutional clients of Westar Capital and Baker Young Stockbrokers who acted as Joint Lead managers to the Issue.
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has initiated an Expanded Access Program (‘EAP’) in the US with Santhera Pharmaceuticals (SIX: SANN, ‘Santhera’) for idebenone in patients with Duchenne Muscular Dystrophy (‘DMD’) who are in respiratory decline.
Houston and London - Cell Medica, a leader in cellular immunotherapy for the treatment of cancer, announced today the appointment of Kevin S. Boyle, Sr. as Chief Financial Officer, based in Houston, TX. With over 20 years of financial and capital markets experience, Kevin joins the senior executive team as the company prepares for ground-breaking clinical trials to investigate cancer treatments utilizing Cell Medica’s innovative chimeric antibody receptor (CAR) and engineered T cell receptor (TCR) cell therapies.
Sydney, Australia - Recce Pharmaceuticals Ltd (ASX: RCE), the company developing a new class of synthetic antibiotics, today announced it has submitted additional data to the US Food and Drug Administration (FDA), including an additional communication request.
Stevenage, UK – Funding from Innovate UK, the UK’s Innovation agency, is enabling UK anti-infectives company Auspherix to expand into new therapeutic indications and test the activity of its new class of organogold antibacterial compounds against bacteria that cause respiratory infections including life-threatening lung infections such as hospital-acquired bacterial pneumonia (HABP). As the second most common hospital acquired infection, HABP is the primary cause of death in intensive care units with a mortality rate of ~30%.